[Pseudoporphyria and coxib].
Schmutz
J-L
JL
Barbaud
A
A
Trechot
P
P
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001706:Biopsy; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D003937:Diagnosis, Differential; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D005260:Female; D020275:Guillain-Barre Syndrome / Q000188:drug therapy; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D008875:Middle Aged; D011164:Porphyrias / Q000139:chemically induced* / Q000175:diagnosis; D011720:Pyrazoles / Q000009:adverse effects*; D012867:Skin / Q000473:pathology; D013449:Sulfonamides / Q000009:adverse effects*; D013450:Sulfones / Q000009:adverse effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib